A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

Canadian Journal of Psychiatry

Volumn 51, Issue 12, 2006, Pages 783-790

  Papakostas, George I ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Major depressive disorder; Moclobemide; Monoamine oxidase inhibitor; Selective serotonin reuptake inhibitor

Indexed keywords

MOCLOBEMIDE; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; NAUSEA; OUTPATIENT; REVIEW; SOMNOLENCE; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 33750488113     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370605101208     Document Type: Review

References (41)

1. Papakostas GI, Fava M. Monoamine-based pharmacotherapy. In: Licinio J, editor. Biology of depression: from novel insights to therapeutic strategies. Weinheim (DE): Wiley-VCH Verlag; 2005.
2. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
3. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, and others. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005;25:336-41.
4. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
5. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99.
6. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-8.
7. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
8. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999;20:226-47.
9. Orsel Donbak S, Turkcapar MH, Ozturk Kilic EZ, Demirergi N, Akdemir A, Sirin A, and others. Moclobemide and sertraline in the treatment of depressive disorders: a comparative study. Acta Psychiatr Belg 1995;95:139-51.
10. Duarte A, Mikkelsen H, Delini-Stula A. Moclobemide versus fluoxetine for double depression: a randomized double-blind study. J Psychiatr Res 1996;30:453-8.
11. Lapierre YD, Joffe R, McKenna K, Bland R, Kennedy S, Ingram P, and others. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci 1997;22:118-26.
12. Sogaard J, Lane R, Latimer P, Behnke K, Christiansen PE, Nielsen B, and others. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999;13:406-14.
13. Pini S, Amador XF, Dell'Osso L, Baldini Rossi N, Cassano P, Savino M, and others. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide. Int Clin Psychopharmacol 2003;18(1):15-21.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
15. Montgomery SA, Asberg A. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
16. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005;66:148-58.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
18. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6:5-30.
19. Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Public Health 1996;17:1-23.
20. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
21. Stassen HH, Angst J, Delini-Stula A. Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry 1999;32(2):56-60.
22. Partonen T, Lonnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996;41:93-9.
23. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord 1994;32:169-77.
24. Barrelet L, Blajev B, Bolzani L, de Sausure C, Kasas A, Van H, and others. Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes. Schweiz Rundsch Med Prax 1991;80:524-8.
25. Williams R, Edwards RA, Newburn GM, Mullen R, Menkes DB, Segkar C. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol 1993;7:155-8.
26. Geerts S, Bruynooghe F, De Cuyper H, Demeulemeester F, Haazen L. Moclobemide versus fluoxetine for major depressive episodes. Clin Neuropharmacol 1994;17 Suppl 1:S50-S57.
27. Lonnqvist J, Sintonen H, Syvalahti E, Appelberg B, Koskinen T, Mannikko T, and others. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994;89:363-9.
28. Gattaz WF, Vogel P, Kick H, Kohnen R. Moclobemide versus fluoxetine in the treatment of inpatients with major depression. J Clin Psychopharmacol 1995;15(4 Suppl 2):35S-40S.
29. Reynaert C, Parent M, Mirel J, Janne P, Haazen L. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology (Berl) 1995;118:183-7.
30. Bocksberger JP, Gachoud JP, Richard J, Dick P. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. Eur Psychiatry 1993;8:319-24.
31. Bougerol T, Uchida C, Gachoud JP, Kohler M, Mikkelsen H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial. Psychopharmacology (Berl) 1992;106 Suppl:S102-S108.
32. Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, and others. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-36.
33. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48:894-901.
34. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-31.
35. Haffmans PM, Timmerman L, Hoogduin CA. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Int Clin Psychopharmacol 1996;11:157-64.
36. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6.
37. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-7.
38. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7.
39. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000;34(1):3-10.
40. Khan A, Khan SR, Shankles EB, Polissar NL. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions Rating Scale in antidepressant clinical trials. Int Clin Psychopharmacol 2002;17:281-5.
41. Khan A, Brodhead AE, Kolts RL. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions Rating Scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol 2004;19:57-60.